Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 1
2014 1
2016 1
2020 6
2021 9
2022 6
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes.
Hallakou-Bozec S, Vial G, Kergoat M, Fouqueray P, Bolze S, Borel AL, Fontaine E, Moller DE. Hallakou-Bozec S, et al. Among authors: fouqueray p. Diabetes Obes Metab. 2021 Mar;23(3):664-673. doi: 10.1111/dom.14277. Epub 2020 Dec 29. Diabetes Obes Metab. 2021. PMID: 33269554 Free PMC article. Review.
Long-term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes (TIMES 2): A 52-week, open-label, multicentre phase 3 trial.
Dubourg J, Fouqueray P, Quinslot D, Grouin JM, Kaku K. Dubourg J, et al. Among authors: fouqueray p. Diabetes Obes Metab. 2022 Apr;24(4):609-619. doi: 10.1111/dom.14613. Epub 2021 Dec 27. Diabetes Obes Metab. 2022. PMID: 34866306 Free PMC article. Clinical Trial.
Imeglimin: A Clinical Pharmacology Review.
Chevalier C, Fouqueray P, Bolze S. Chevalier C, et al. Among authors: fouqueray p. Clin Pharmacokinet. 2023 Oct;62(10):1393-1411. doi: 10.1007/s40262-023-01301-y. Epub 2023 Sep 15. Clin Pharmacokinet. 2023. PMID: 37713097 Review.
Reduced lactic acidosis risk with Imeglimin: Comparison with Metformin.
Theurey P, Vial G, Fontaine E, Monternier PA, Fouqueray P, Bolze S, Moller DE, Hallakou-Bozec S. Theurey P, et al. Among authors: fouqueray p. Physiol Rep. 2022 Mar;10(5):e15151. doi: 10.14814/phy2.15151. Physiol Rep. 2022. PMID: 35274817 Free PMC article.
Evaluation of PXL065 - deuterium-stabilized (R)-pioglitazone in patients with NASH: A phase II randomized placebo-controlled trial (DESTINY-1).
Harrison SA, Thang C, Bolze S, Dewitt S, Hallakou-Bozec S, Dubourg J, Bedossa P, Cusi K, Ratziu V, Grouin JM, Moller DE, Fouqueray P. Harrison SA, et al. Among authors: fouqueray p. J Hepatol. 2023 May;78(5):914-925. doi: 10.1016/j.jhep.2023.02.004. Epub 2023 Feb 18. J Hepatol. 2023. PMID: 36804402 Clinical Trial.
Beneficial Effects of the Direct AMP-Kinase Activator PXL770 in In Vitro and In Vivo Models of X-Linked Adrenoleukodystrophy.
Monternier PA, Parasar P, Theurey P, Gluais Dagorn P, Kaur N, Nagaraja TN, Fouqueray P, Bolze S, Moller DE, Singh J, Hallakou-Bozec S. Monternier PA, et al. Among authors: fouqueray p. J Pharmacol Exp Ther. 2022 Aug;382(2):208-222. doi: 10.1124/jpet.122.001208. Epub 2022 Jun 28. J Pharmacol Exp Ther. 2022. PMID: 35764327 Free PMC article.
23 results